| Product Name | FGF23 ELISA kit (Human) |
|---|---|
| Description | This assay has high sensitivity and excellent specificity for detection of Fibroblast Growth Factor 23 (FGF23). No significant cross-reactivity or interference between Fibroblast Growth Factor 23 (FGF23) and analogues was observed. |
| Synonyms | ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor |
| Method | Sandwich |
| Detection Range | 15.6-1,000pg/mL |
| Sensitivity | 6.5pg/mL |
| Target | FGF23 |
| Specificity | This assay has high sensitivity and excellent specificity for detection of Fibroblast Growth Factor 23 (FGF23). No significant cross-reactivity or interference between Fibroblast Growth Factor 23 (FGF23) and analogues was observed. |
| Reactivity | Human |
| Sample Types | Serum, Plasma, Tissue Homogenates, Cell Lysates, Cell Culture Supernates And Other Biological Fluids |
| Reconstitution | 1.Prepare all reagents, samples and standards; 2.Add 100uL standard or sample to each well.Incubate 2 hours at 37℃; 3.Aspirate and add 100uL prepared Detection Reagent A.Incubate 1 hour at 37℃; 4.Aspirate and wash 3 times; 5.Add 100uL prepared Detection Reagent B.Incubate 30 minutes at 37℃; 6.Aspirate and wash 5 times; 7.Add 90uL Substrate Solution.Incubate 10-20 minutes at 37℃; 8.Add 50uL Stop Solution.Read at 450nm immediately. |
| Uniprot | Q9GZV9 |
| Storage | 4°C for 1 month/ -20°C for long-term(within shelf life) |
| Notes | Colormetric |
| References | Prognostic impact of renal function in precapillary pulmonary hypertension;FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients;Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism;Prognostic impact of renal function in precapillary pulmonary hypertension.;Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina;An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer;Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique?;High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23;Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation;Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients;ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.;Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity;Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children;Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study;Disconnection of pulmonary and systemic arterial stiffness in COPD;Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients;Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma;Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients;Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases;PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS;Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease;Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?;THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS;THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡;The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations;Genetic and clinical profile of patients with hypophosphatemic rickets;Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease; |
| Supplier | Cloud Clone |
PROTOCOLS:
SEA746Hu All Research Products are sold for laboratory RESEARCH USE ONLY and ARE NOT TO BE USED FOR HUMAN OR ANIMAL THERAPEUTIC OR DIAGNOSTIC APPLICATIONS. The information presented is believed to be accurate; however, said information and products are offered without warranty or guarantee since the ultimate conditions of use and the variability of the materials treated are beyond our control. Nothing disclosed herein is to be construed as a recommendation to use our products in violation of any patents. ARP American Research Products, Inc. does not submit its products for regulatory review by any government body or other organization, and we do not validate them for clinical, therapeutic or diagnostic use, or for safety and effectiveness. You are solely responsible for making sure that the way you use the products complies with applicable laws, regulations and governmental policies and for obtaining all necessary approvals, intellectual property rights, licenses and permissions that you may need related to your use. Under no circumstances shall ARP American Research Products, Inc. be liable for damages, whether consequential, compensatory, incidental or special, strict liability or negligence, breach of warranty or any other theory arising out of the use of the products available from ARP American Research Products, Inc. Nothing contained herein warrants that the use of the products will not infringe on the claims of any patents covering the product itself or the use thereof in combination with other products or in the operation of any process. ARP American Research Products, Inc. disclaims any and all representations or warranties of any kind whatsoever, express or implied, including without limitation any implied warranties of merchantability or fitness for a particular purpose, of non-infringement, or regarding results obtained through the use of any product, whether arising from a statute or otherwise in law or from a course of performance, dealing or usage of trade.
